Cargando…
Pre-diagnosis urine exosomal RNA (ExoDx EPI score) is associated with post-prostatectomy pathology outcome
PURPOSE: ExoDx Prostate IntelliScore (EPI) is a non-invasive urine exosome RNA-based test for risk assessment of high-grade prostate cancer. We evaluated the association of pre-biopsy test results with post-radical prostatectomy (RP) outcomes to understand the potential utility of EPI to inform inva...
Autores principales: | Kretschmer, Alexander, Tutrone, Ronald, Alter, Jason, Berg, Elena, Fischer, Christian, Kumar, Sonia, Torkler, Phillipp, Tadigotla, Vasisht, Donovan, Michael, Sant, Grannum, Skog, Johan, Noerholm, Mikkel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8994717/ https://www.ncbi.nlm.nih.gov/pubmed/35084544 http://dx.doi.org/10.1007/s00345-022-03937-0 |
Ejemplares similares
-
Clinical utility of the exosome based ExoDx Prostate(IntelliScore) EPI test in men presenting for initial Biopsy with a PSA 2–10 ng/mL
por: Tutrone, Ronald, et al.
Publicado: (2020) -
Predicting high-grade prostate cancer at initial biopsy: clinical performance of the ExoDx (EPI) Prostate Intelliscore test in three independent prospective studies
por: Margolis, Erik, et al.
Publicado: (2021) -
ExoDx prostate test as a predictor of outcomes of high-grade prostate cancer – an interim analysis
por: Tutrone, Ronald, et al.
Publicado: (2023) -
A urine-based Exosomal gene expression test stratifies risk of high-grade prostate Cancer in men with prior negative prostate biopsy undergoing repeat biopsy
por: McKiernan, James, et al.
Publicado: (2020) -
Validation of a CE-IVD, urine exosomal RNA expression assay for risk assessment of prostate cancer prior to biopsy
por: Kretschmer, Alexander, et al.
Publicado: (2022)